• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SIMEPREVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • SIMEPREVIR chembl:CHEMBL501849 Approved

    Alternate Names:

    TMC 435
    OLYSIO
    SIMEPREVIR
    TMC-435350
    TMC 435350
    TMC435350
    TMC-435
    OLYSIO®
    SIMEPREVIR SODIUM
    TMC435
    pubchem.compound:24873435
    chemidplus:923604-59-5
    rxcui:1482790
    drugbank:06290
    chembl:CHEMBL501849

    Drug Info:

    (0 More Sources)

    Publications:

    D'Offizi G et al., 2017, Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection., New Microbiol
    Manns M et al., 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet
    Forns X et al., 2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial., Gastroenterology
    Mori N et al., 2017, IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C., Hepatol Res
  • SIMEPREVIR   IFNL4

    Interaction Score: 3.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28072888 27027531 24907224 24602923


    Sources:
    PharmGKB

  • SIMEPREVIR   IFNL3

    Interaction Score: 2.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28072888 24907224 24602923


    Sources:
    PharmGKB FDA

  • SIMEPREVIR   SLCO1B3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMEPREVIR   CYP2C8

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMEPREVIR   SLCO1B1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMEPREVIR   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMEPREVIR   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMEPREVIR   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SIMEPREVIR   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PharmGKB: simeprevir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    D'Offizi G et al., 2017, Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection., New Microbiol
    Forns X et al., 2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial., Gastroenterology
    Manns M et al., 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet

  • TTD: Simeprevir

    • Version: 2020.06.01

    Alternate Names:
    D00TLP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL501849

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Simeprevir

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21